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Background: Despite the survival benefit of implantable-cardioverter-defibrillators (ICDs), the vast majority of
patients receiving an ICD for primary prevention do not receive ICD therapy. We sought to assess the role of
heterogeneous scar area (HSA) identified by late gadolinium enhancement cardiovascular magnetic resonance
(LGE-CMR) in predicting appropriate ICD therapy for primary prevention of sudden cardiac death (SCD).
Methods: From September 2003 to March 2011, all patients who underwent primary prevention ICD implantation
and had a pre-implantation LGE-CMR were identified. Scar size was determined using thresholds of 4 and 6
standard deviations (SD) above remote normal myocardium; HSA was defined using 3 different criteria; as the
region between 2 SD and 4 SD (HSA2-4SD), between 2SD and 6SD (HSA2-6SD), and between 4SD and 6SD
(HSA4-6SD). The end-point was appropriate ICD therapy.
Results: Out of 40 total patients followed for 25 ± 24 months, 7 had appropriate ICD therapy. Scar size measured by
different thresholds was similar in ICD therapy and non-ICD therapy groups (P = NS for all). However, HSA2-4SD and
HSA4-6SD were significantly larger in the ICD therapy group (P = 0.001 and P = 0.03, respectively). In multivariable
model HSA2-4SD was the only significant independent predictor of ICD therapy (HR = 1.08, 95%CI: 1.00-1.16, P = 0.04).
Kaplan-Meier analysis showed that patients with greater HSA2-4SD had a lower survival free of appropriate ICD
therapy (P = 0.026).
Conclusions: In primary prevention ICD implantation, LGE-CMR HSA identifies patients with appropriate ICD
therapy. If confirmed in larger series, HSA can be used for risk stratification in primary prevention of SCD.
Keywords: Cardiovascular magnetic resonance, Late gadolinium enhancement, Implantable cardioverter
defibrillator, Scar heterogeneityBackground
Sudden cardiac death (SCD) accounts for 5.6-15% of
annual mortality in the United States and industrialized
countries [1] and is a major cause of mortality in pa-
tients with advanced heart failure and coronary heart
disease. Implantable cardioverter-defibrillators (ICD)
have been found to significantly reduce arrhythmic death
in this population [2]. Based on the MADIT-II and* Correspondence: rnezafat@bidmc.harvard.edu
1Department of Medicine, Boston, MA, USA
3Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215,
USA
Full list of author information is available at the end of the article
© 2013 Rayatzadeh et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumSCD-HeFT trials [3], current guidelines recommend
ICD implantation as a class I indication for primary
prevention of SCD in patients with a left ventricular
ejection fraction (LVEF) ≤ 30% as well as those with
LVEF ≤ 35% that are New York Heart Association (NYHA)
heart failure class II or III [4].
Current guidelines use LVEF as the major risk stratifier
for primary prevention ICD implantation [4]. While
efficacious, the majority of patients receiving an ICD for
primary prevention do not utilize this expensive therapy
[5]. On the other hand, many patients with an LVEF > 35%
may develop potentially lethal ventricular arrhythmias (e.g.
ventricular tachycardia and ventricular fibrillation) andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ing the patients at risk of SCD and finding the major pre-
dictors of SCD that play a role either independently or in
conjunction with LVEF [6-8].
Multiple mechanisms underlie ventricular arrhythmias.
Much evidence suggests a link between ventricular scar
and arrhythmogenicity [9-12]. Late gadolinium enhance-
ment cardiovascular magnetic resonance (LGE-CMR)
can accurately characterize areas of myocardial injury
and scar [13,14]. In one study of patients with LV dys-
function, infarct tissue heterogeneity on LGE-CMR was
the only significant predictor of inducible sustained
monomorphic VT [15]. However, VT inducibility is a
surrogate end-point and may not reflect clinical efficacy.
In the present study, we sought to investigate the correl-
ation between LGE-CMR tissue heterogeneity and the
occurrence of appropriate ICD therapy.
Methods
Study design and patient selection
The Beth Israel Deaconess Medical Center clinical CMR
database was queried to identify all patients undergoing
ICD implantation for primary SCD prevention from
September 2003 to March 2011 who also had a pre-
implantation CMR. Patients with ischemic and idio-
pathic non-ischemic cardiomyopathies were included.
All patients with hypertrophic, inflammatory, infiltrative,
and arrhythmogenic right ventricular cardiomyopathies
were excluded. Patient demographics and clinical follow-
up records from the hospital electronic medical records
were reviewed.
The study was carried out with Beth Israel Deaconess
Medical Center Institutional Review Board approval and
written informed consent was waived. The authors had
full access to the data and take responsibility for its in-
tegrity. All authors have read and agreed to the manu-
script as written.
Cardiovascular magnetic resonance
CMR was performed on a Philips 1.5 T (Philips Medical
Systems, Amsterdam, Netherlands) CMR scanner with a
commercial 5-element cardiac-surface coil. Cine images
were acquired in a contiguous LV short-axis orientation
with an electrocardiography-gated, breath-hold, steady-
state free-precession sequence with full LV coverage
(8-mm slice thickness, 2-mm interslice gap, in-plane
spatial resolution 2 × 2 mm, 30 ms temporal resolution).
LGE-CMR was performed 15 minutes after the intra-
venous administration of 0.2 mmol/kg gadolinium-
DTPA (Magnevist; Schering, Berlin, Germany) with a 2-
dimensional breath-hold, segmented inversion-recovery
sequence (inversion time optimized by the Look-Locker se-
quence [inversion time scout] to null normal myocardium)
acquired in the same orientation (short-axis stack) as thecine images, with the following imaging parameters: 8-mm
slice thickness, 2-mm interslice gap, repetition time (TR)
4.2 ms, echo time (TE) 1.8 ms, flip angle 20°, field of view
320 × 320 mm2, matrix 160 × 160, and spatial resolution
2 × 2 mm2. In 9 patients LGE was performed using a 3D
phase sensitive inversion recovery sequence (PSIR) with the
following imaging parameters 10-mm slice thickness,
5-mm spacing between slices, TR 4.2 ms, TE 1.8 ms, flip
angle 15°, field of view 320 × 320 mm2, matrix size 176 × 156,
and spatial resolution 1.8 × 2.0 mm2.
CMR analysis
CMR analyses were performed with commercially
available software (QMassMR version 7.1.0; MedisInc,
Leiden, Netherlands). LV endocardial and epicardial
borders on both cine and LGE images were measured
by planimetry, with special care taken to exclude papil-
lary muscles and the intertrabecular blood pool. Left
and right ventricular volume, mass, and ejection frac-
tion were measured from the cine short-axis images
using standard techniques [16].
The LV short-axis stack of LGE images was first assessed
visually for the presence of LGE by two independent,
experienced readers and disagreements were adjudi-
cated by a senior observer. The readers were blinded to
the outcome data.
The mean grayscale signal intensity (SI) and standard
deviation (SD) for normal LV myocardium were mea-
sured for each patient, with a region of interest placed in
a portion of nulled myocardium (i.e., without LGE on
visual inspection).
In order to identify the best SI threshold of scar detec-
tion as well as HSA, scar size was determined using a
threshold of 4 or 6 SD above the mean of the remote
normal myocardium and by manual tracing (Figure 1);
HSA was defined as the difference between 2 SD and 4
SD (HSA2-4SD), between 2SD and 6SD (HSA2-6SD) and
between 4SD and 6SD (HSA4-6SD). The amount of LGE
for each group was expressed in grams.
ICD implantation and follow-up
All devices were implanted using standard surgical tech-
nique; choice of device was at the discretion of the
implanting physician and the device was activated at
completion of implantation.
All devices were programmed for both anti-tachycardial
pacing (ATP) and shock with three zones of therapy includ-
ing shock for ventricular fibrillation (VF), ATP followed by
shock for fast VT, and a monitored zone for slower VT.
Exact therapy settings were adjusted at the discretion of the
implanting physician.
Devices were interrogated at 1 and 3 months after im-
plantation and every 6 months thereafter in the device






Figure 1 Assessment of heterogeneous scar area (HSA). A) Mid-ventricular short axis LGE image of a patient with considerable LGE (red
arrow) in ventricular septum and anterior wall, and a region of interest in normal myocardium in the inferior wall (ROI; orange box) used to
define thresholds for LGE. RV indicates right ventricle; LV, left ventricle. B) Endocardial (red) and epicardial (green) borders were outlined
manually. Grayscale threshold 2SDs above the mean signal intensity of the ROI (red shading) was outlined. C) Grayscale threshold 4SDs above the
mean signal intensity of the ROI (red shading) were considered as scar core and is shown in red shading. D) HSA2-4SD defined as the signal
intensity between ≥2SD and <4SD is shown in yellow shading, superimposed on scar core (>4SD) in red shading.
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device was interrogated, and recorded events and ICD
therapy reviewed. Stored electrograms prior to device
therapy were assessed by an experienced cardiologist
blinded to CMR findings. Appropriate ICD therapy was
defined as antitachycardia pacing or shocks delivered for
ventricular tachyarrhythmias [17-20].
Statistics
Continuous variables are presented as mean ± SD.
Categorical variables are presented in number and per-
centage. Pre-ICD implantation NYHA class is presented
in median ± interquartile range of 25-75%. Survival time
for appropriate ICD therapy outcome was defined to be
the time (number of days) from ICD implantation to the
appropriate ICD therapy. The end of the follow-up
period was September 30, 2011. If the patient did not
have an appropriate ICD therapy in the follow-up
period, then the patient’s outcome was considered to be
censored. Univariate Cox regression analysis was utilized
to assess the association between each variable and the
survival function of appropriate ICD therapy. A correl-
ation matrix was made to assess the association amongthe predictors. Statistically significant variables from the
univariate analysis were identified and entered into the
Cox’s multivariable model as exploratory analysis only,
due to the limited number of events. Variables such as
HSA2-4SD and HSA4-6SD were both significant but were
highly correlated; therefore, only one was entered into
the multivariate model (HSA2-4SD was more significant).
Since HSA2-4SD was found to be an independent pre-
dictor of appropriate ICD therapy, the study population
was divided into 2 groups based on the median value of
the HSA2-4SD (5.9 g), and the event-rate of both cohorts
was further analyzed by the method of Kaplan–Meier.
The log-rank test was used to compare Kaplan-Meier
survival curve. All statistical analyses were performed
using SAS (v9.2, SAS Institute, Cary, NC). A P value of
<0.05 was considered to be significant.
Results
Clinical and demographic data
A total of 41 patients who were referred for ICD im-
plantation as the primary prevention of SCD and had a
pre-ICD implantation LGE-CMR available, were identi-
fied. Baseline characteristics of the entire cohort are






n = 7 n = 33
LVM (g) 173 ± 30 160 ± 47 0.599
LVMI (g/m2) 91 ± 14 82 ± 20 0.369
LVEF (%) 23 ± 6.5 31 ± 9 0.04
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ICD implantation which led to non-arrhythmic death 2 days
after the procedure and was excluded from analysis. During
the 25 ± 24 months follow-up, 4 patients died. Primary indi-
cation for cardiac MRI was assessment of cardiomyopathy
(9 patients), LV and RV function (5 patients), and viability
and scar assessment (26 patients).LVEDV (ml) 263 ± 34 268 ± 107 0.831
LVEDVI (ml/m2) 140 ± 29 137 ± 45 0.559
LVESV (ml) 202 ± 35 195 ± 93 0.546
RVEDV (ml) 128 ± 19 160 ± 71 0.369
RVEDVI (ml/m2) 69 ± 12 78 ± 20 0.443
RVESV (ml) 66 ± 5.5 77 ± 41 0.719
RVEF (%) 48 ± 8 51 ± 12 0.332
LGE presence (%) 6 (86) 19 (57) 0.155ICD follow-up data
After a mean follow-up of 25 ± 24 months (median = 13,
IQR: 7–35 months), appropriate ICD therapy occurred
in 7 (17.5%) patients including 2 patients who received
ATP and 5 patients who received ICD shocks. One of
the patients with ICD discharge underwent VT ablation.
Two patients in the group without ICD therapy received
inappropriate shocks for atrial fibrillation.LGE4SD (g) 44 ± 29 27 ± 31 0.112
LGE6SD (g) 32 ± 25 21 ± 27 0.193
Visual (g) 34 ± 23 24 ± 28 0.245
HSA2-4SD (g) 17 ± 12 5 ± 7 0.001
HSA4-6SD (g) 11 ± 10 5 ± 7 0.038
LVM:Left ventricular mass; LVMI:left ventricular mass index; LVEDV:left
ventricular end-diastolic volume; LVEDVI:left ventricular end-diastolic volume
index; LVESV:left ventricular end-systolic volume; RVEDV:right ventricular end-
diastolic volume; RVEDVI:right ventricular end-diastolic volume index; RVESV:
left ventricular end-systolic volume; RVEF:right ventricular ejection fraction;
LGE: late gadolinium enhancement; HSA:heterogenous scar area.
* Univariate Cox’s proportional hazard model.
# HSA2-4SD and HSA4-6SD were highly correlated (r=0.69, p-value: 0.0001), so
only HSA2-4SD was entered into the multivariate model.CMR data
Data from LGE-CMR and function analysis are summa-
rized in Table 2. There was a trend for greater scar size
in the appropriate ICD therapy group by the 4 SD
(P = 0.11) and 6 SD (P = 0.19) definitions. HSA was sig-
nificantly greater in the appropriate ICD therapy group
(HSA2-4SD, P = 0.001; HSA4-6SD, P = 0.03) (Table 2).
LVEF was also lower in the appropriate ICD therapy
group (P = 0.04). The other functional and volumetric mea-






n = 7 n = 33
Age (year) 66 ± 10 61 ± 11 0.824
Sex (M), n (%) 6 (86) 23 (70) 0.323
ICM, n (%) 5 (71) 15 (45) 0.427
BiV, n (%) 2 (28) 9 (27) 0.729
Diabetes, n (%) 5 (71) 9(27) 0.081#
Hypertension, n (%) 6 (86) 24 (72) 0.819
Dyslipidemia, n (%) 3 (43) 18(54) 0.233
Beta-blocker, n (%) 5 (71) 30 (91) 0.453
ACE-inhibitor, n (%) 7 (100) 31 (94) 0.996
Anti-arrhythmic, n (%) 0 2 (6) 0.995
Aspirin, n (%) 5 (71) 26 (79) 0.493
Pre-ICD NYHA 3 ± 1 3 ± 1 0.810
Inappropriate ICD
therapy
0 2 (6) 0.996
BiV: Biventricular pacemaker; ICM: ischemic cardiomyopathy; ACE: angiotensin
converting enzyme; Echo: echocardiography; NYHA: new york
heart association.
* Univariate Cox’s proportional hazard model.
# was considered clinically significant and was entered into the
multivar model.Univariate analysis showed a significant relationship
between HSA and ICD therapy, whether it is defined
by HSA2-4SD (HR 1.11, chi-square = 10.73, p = 0.001),
HSA4-6SD (HR 1.09, chi-square = 4.28, p = 0.039), or
HSA2-6SD (HR 1.6, chi-square = 9.09, p-0.003). Due to
the limited number of events, a multivariable Cox
model was constructed as exploratory analysis to con-
trol for the possible confounding effects of LVEF and
diabetes on the relationship between HSA2-4SD and
ICD therapy. HSA2-4SD (HRadjusted1.08, 95%CI: 1.00-1.16,
P = 0.04) remained a significant predictor of ICD therapy
(Table 3), suggesting that for each gram increase in the
HSA2-4SD, there is an 8% increase in the risk of appropri-
ate ICD therapy.Table 3 Multivariate Cox proportional hazard regression
HR 95% CI P-value
CMR-LVEF (%) 0.95 0.84-1.07 0.409
DM 2.61 0.39-17.49 0.321
HSA2-4SD (gr) 1.08 1.00-1.16 0.041
DM:diabetes mellitus; HSA:hetreogenous scar area; HR: hazard ratio.
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with HSA2-4SD greater than the median (5.9 grams) had a
lower survival free of appropriate ICD therapy (P = 0.026).Discussion
In this retrospective study of patients with ischemic and
non-ischemic cardiomyopathy undergoing a CMR study
prior to ICD implantation for primary prevention of
SCD, we found that scar heterogeneity identified a sub-
set of patients who subsequently had appropriate ICD
therapy. Our data also showed a trend for LGE-CMR
scar size as a predictor for ICD therapy. Additionally, in
multivariate analysis, HSA was the only independent
predictor which had significant impact on appropriate
ICD therapy, while LVEF did not.
Current guidelines recommend ICD implantation for
primary prevention of SCD based on LVEF thresholds
[3,4,21]. Based on this metric, a large number of patients
become eligible for this expensive treatment, but in a
majority of patients receiving ICDs for primary preven-
tion of SCD, appropriate ICD therapy does not occur
during reported follow-up times [5]. Thus, there is a
growing effort to better risk stratify patients with reduced
LVEF most likely to benefit from prophylactic ICD
implantation [6,7].
The major cause of SCD is ventricular tachyarrhyth-
mia including VT and VF. Re-entry circuits appear to
be a common mechanism underlying these ventricular
arrhythmias [22] and the presence of myocardial scarFigure 2 Kaplan-Meier analysis shows that patients with HSA2-4SD
greater than the median (5.9 grams) had lower survival free of
appropriate ICD therapy (dashed line) whereas the patients with
smaller HSA2-4SD (≤ 5.9 grams) had higher longer survival free of
ICD firing (solid line).has been indentified to be linked to the development of
re-entrant arrhythmias [22,23]. LGE-CMR allows us to
delineate myocardial fibrosis and scar tissue [24,25].
LGE presence has been shown to correlate with ven-
tricular arrhythmia and ICD therapy in ischemic and
non-ischemic cardiomyopathies [12]. In our study, the
presence of scar was seen more frequently in patients
requiring appropriate ICD therapy. However, 57% of
patients who did not have ICD therapy had LGE.
In previous studies it has been shown that scar size in
LGE-CMR [26] or in combination with electroanatomical
mapping [27] can predict ventricular arrhythmia in patients
with cardiomyopathy. Our data demonstrate not only that
the extent of myocardial scar by different definitions (4SD,
6SD and visual thresholds) was larger in the appropriate
ICD therapy group, but also the heterogeneity of scar is an
independent predictor of appropriate ICD therapy. In previ-
ous studies, it has been reported that the extent of LV scar
as well as peri-infarct zone were independent predictors of
VT inducibility [15,28].
The partial volume effect is defined as an admixture of
both infarcted (high SI) and noninfarcted (low SI) tissue.
With averaging the 2 different SIs will be averaged, and
those particular voxels will be represented by an inter-
mediate SI (gray), affecting the HSA detection and
measurement. The partial volume effect could result
from volume-averaging effects of an area of uniformly
fibrotic tissue (dense infarct scar) with an adjacent area
of preserved, viable myocardium, particularly in situa-
tions in which spatial resolution is limited [24,28,29]. In
this case, anatomically, there would be a narrow border
between fibrotic scar and viable myocardium, and the
limited spatial resolution would render an apparent
intermediate SI in that border region. Partial volume
effects due to averaging of normal and necrotic tissue
have been demonstrated by LGE-CMR in experimental
animal studies [24,29-31]. However, a second explan-
ation is that the gray zone arises from the intermingling
of preserved myocardium with bundles of fibrotic, in-
farcted scar within the same voxel. In this case, there
would be a more gradual anatomic transition from
dense, infarct core to preserved tissue beyond the infarct
periphery. The latter mechanism is supported by patho-
logical data [32,33].
We also wish to emphasize that having lower HSA
does not invalidate previous risk stratification strategies
based on other clinical factors. Decisions to exclude pa-
tients from receiving an ICD should not be based solely
on HSA quantification, particularly in patients already
deemed high risk prior to their CMR.
Our data in this study agree with previous studies.
Schmidt and colleagues [15] studied 47 patients with
a prior MI who underwent ICD implantation. They
reported that infarct tissue heterogeneity was strongly
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tachycardia, and was the single significant factor in a
stepwise logistic regression.
To our knowledge, our study has the longest follow-up
time and includes patients over a long time period from
2003 to 2011 which makes it unique among similar
studies. Although some other studies have looked into a
similar hypothesis, they all had a shorter follow-up time.
Roes et al. showed that after a mean follow-up of
8.5 months, infarct gray zone was the strongest predictor
of appropriate ICD therapy in patients with prior MI
[34]. In addition, we have defined infarct heterogeneity
by two different criteria to find the best metric that cor-
relates well with appropriate ICD therapy. Scott et al.
reported that during 19 months of follow-up of patients
with coronary artery disease, appropriate ICD therapy
occurred in patients with a greater scar size [35]. Iles
et al. studied patients with cardiomyopathy and found
that during 18 months of follow-up appropriate ICD
therapy occurred more frequently in patients with LGE
[12]. Compared to previous studies, which have mainly
included ischemic populations, we have enrolled those
with ischemic and non-ischemic cardiomyopathy.
A number of limitations of the current study need to
be addressed. First, this study is a single center retro-
spective cohort and the results should be supported by a
prospective multicenter trial. Second, the small sample
size in this study prevented us from entering more
variables into multivariable model, some of which may
have potential confounding effects. Furthermore, the
presented multivariable model is intended to be explora-
tory in nature, rather than demonstrating the independ-
ent relationship between HSA and ICD therapy. Also,
most of the patients with appropriate ICD therapy had
ischemic cardiomyopathy (71%). The sample size of the
current study does not allow to study the value of LGE-
CMR in CAD versus non-CAD patients. Thus, it is ne-
cessary to conduct a large trial in order to confirm the
results of our study. In several patients with diffuse LGE
in multiple regions of the myocardium, it was challen-
ging to demarcate a region of interest (ROI) to define
normal myocardium. However, great care was made to
exclude regions of LGE and blood pool in the ROI, and
all regions subsequently assigned as scar were verified
visually before proceeding. In our study, 9 patients had
3D PSIR LGE images which were different from 2D LGE
images. Despite this difference, we did not notice any
difference in the result by excluding this subset of
patients, presumably due to small size.
Conclusions
In conclusion, LGE-CMR scar tissue heterogeneity is an
important parameter for risk stratification of patients being
considered for primary prevention ICD implantation. Ifsupported by prospective, multicenter trials, LGE-CMR
may emerge as the imaging metric for risk stratification for
primary prevention ICD implantation.
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